Terminated PHASE1 INTERVENTIONAL NCT00125411

Study of Satraplatin (JM-216) in Combination With Docetaxel

Phase I Study of the Oral Platinum Agent Satraplatin (JM-216) in Combination With Docetaxel in Treatment of Advanced Malignancies

Sponsor: Agennix

Conditions Tumors

Interventions satraplatin and docetaxel

Updated 6 times since 2017 Last updated: Mar 22, 2012 Started: Mar 31, 2007 Primary completion: Feb 28, 2009 Completion: Feb 28, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Sponsor decided to discontinue study drug development.

Other terminated trials from Agennix

See all terminations from Agennix

Other Tumors trials with similar outcome

Browse all Tumors trials

Listed as NCT00125411, this PHASE1 trial focuses on Tumors and remains terminated or withdrawn. Sponsored by Agennix, it has been updated 6 times since 2007, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Terminated PHASE1
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE1
Jan 2021 — Jul 2024 [monthly]

Terminated PHASE1
Jun 2018 — Jan 2021 [monthly]

Terminated PHASE1
Feb 2017 — Jun 2018 [monthly]

Terminated PHASE1

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Terminated PHASE1

First recorded

Mar 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Agennix

Data source: Agennix

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Madison, United States